Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Standard Biotools (LAB) Cash from Investing Activities (2016 - 2025)

Historic Cash from Investing Activities for Standard Biotools (LAB) over the last 17 years, with Q3 2025 value amounting to -$6.7 million.

  • Standard Biotools' Cash from Investing Activities rose 7836.67% to -$6.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $61.2 million, marking a year-over-year decrease of 8113.81%. This contributed to the annual value of $363.2 million for FY2024, which is 169460.39% up from last year.
  • According to the latest figures from Q3 2025, Standard Biotools' Cash from Investing Activities is -$6.7 million, which was up 7836.67% from $27.5 million recorded in Q2 2025.
  • Over the past 5 years, Standard Biotools' Cash from Investing Activities peaked at $318.1 million during Q1 2024, and registered a low of -$138.2 million during Q2 2022.
  • Its 5-year average for Cash from Investing Activities is $16.8 million, with a median of -$868000.0 in 2022.
  • In the last 5 years, Standard Biotools' Cash from Investing Activities plummeted by 321351.87% in 2022 and then surged by 507165.9% in 2023.
  • Quarter analysis of 5 years shows Standard Biotools' Cash from Investing Activities stood at -$1.1 million in 2021, then skyrocketed by 3614.85% to $40.2 million in 2022, then crashed by 132.59% to -$13.1 million in 2023, then surged by 296.13% to $25.7 million in 2024, then crashed by 125.97% to -$6.7 million in 2025.
  • Its Cash from Investing Activities stands at -$6.7 million for Q3 2025, versus $27.5 million for Q2 2025 and $14.6 million for Q1 2025.